Study guide
10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures
Key Takeaways Explain This Topic AI
Investigational Product storage facilities must be double-locked, temperature-controlled, and accessible strictly to authorized personnel delegated on the Delegation of Authority Log (ICH E6(R3) Annex 1 2.10 / 21 CFR 312.62).
The Investigational Drug Accountability Record (DAR / IPAL) is a binding legal source document that must record every transaction in real-time: receipt dates, kit/lot numbers, quantities dispensed/returned, subject IDs, balance on hand, and dispenser initials.
Participant medication adherence must be calculated systematically at each return visit using the formula: (Quantity Dispensed - Quantity Returned) / Quantity Prescribed * 100%, with all discrepancies investigated and documented.
Final close-out requires 100% mathematical reconciliation across all received, dispensed, returned, lost, and unused investigational units before study termination.
On-site destruction of IP requires prior written authorization from the sponsor, adherence to institutional environmental and DEA Schedule rules, and execution of a formal Certificate of Destruction signed by two witnesses.
Last updated: August 2026
IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures
Core Regulatory Standard: Under ICH E6(R3) Annex 1 section 2.10 (Investigational Product(s)) and 21 CFR 312.62 (Investigator Recordkeeping and Product Control) , the Principal Investigator bears ultimate legal responsibility for maintaining complete, accurate, and real-time accountability for all investigational products delivered to the site. Failure to account for every single unit of investigational drug or device represents one of the most frequent citations on FDA Form 483 inspection observations and major audit findings.
1. Physical Storage Security & Access Control
Investigational products must be segregated from commercial pharmacy inventory and stored in a secure environment that prevents diversion, contamination, and unauthorized access. ┌───────────────────────────────────────────────────────────────────────────┐
- │ IP STORAGE SECURITY REQUIREMENTS │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. DOUBLE-LOCK SECURITY: Stored in a locked dedicated room, locked │
- │ cabinet, or locked refrigerator inside an access-controlled area. │
- │ 2. RESTRICTED ACCESS: Physical keys or electronic keycards are issued │
- │ ONLY to individuals explicitly delegated IP management duties on the │
- │ Delegation of Authority Log (DOAL) (e.g., Research Pharmacist, CRC). │
- │ 3. PHYSICAL SEGREGATION: IP must never be mixed with routine commercial │
- │ hospital stock or products from other clinical protocols. │
- │ 4. CONTROLLED SUBSTANCES (DEA SCHEDULE II-V): Investigational narcotics │
- │ or controlled substances must be stored in a permanently bolted, │
- │ substantially constructed steel safe meeting 21 CFR Part 1301.72 rules.│
- └───────────────────────────────────────────────────────────────────────────┘
- Segregation of Unblinded Materials
In double-blind studies where the site pharmacy prepares open-label or unblinded formulations (e.g., active drug ampoules vs. normal saline vials), unblinded stock and unblinded preparation binders must be stored in a separate, locked compartment accessible only to the unblinded research pharmacist. Blinded study coordinators and investigators must never have access to this area.
2. The Investigational Drug Accountability Log (DAR / IPAL)
The Drug Accountability Record (DAR) —also called the Investigational Product Accountability Log (IPAL) —is the primary regulatory document that tracks the full lifecycle of every dosage unit delivered to the trial site. ┌───────────────────────────────────────────────────────────────────────────┐
- │ THE COMPLETE IP ACCOUNTABILITY LIFECYCLE │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ [CENTRAL DEPOT] ──► [SITE RECEIPT] ──► [STORAGE INVENTORY] │
- │ │ │
- │ ▼ │
- │ [DISPENSED TO SUBJECT] │
- │ │ │
- │ ▼ │
- │ [RETURNED BY SUBJECT] │
- │ │ │
- │ ▼ │
- │ [100% FINAL MONITOR RECONCILIATION] │
- │ │ │
- │ ┌──────────────┴──────────────┐ │
- │ ▼ ▼ │
- │ [RETURN TO SPONSOR] [ON-SITE DESTRUCTION] │
- │ (Signed Packing Slip) (Certificate of Destruction) │
- └───────────────────────────────────────────────────────────────────────────┘
- Master vs. Subject-Specific Accountability Logs
Master Drug Accountability Log: Tracks the overall inventory balance of all shipments received at the site, total units dispensed across all subjects, units damaged or wasted, and current balance on hand in the pharmacy vault.
Subject-Specific Dispensing Log: Maintained inside each participant's study binder, recording every kit number dispensed to and returned by that individual subject across all scheduled protocol visits.
Mandatory Regulatory Data Fields on the IPAL (21 CFR 312.62 & ICH 4.6.3)
Log Data Field Description & Regulatory Purpose
Date Received / Transacted Calendar date of receipt from depot, dispensing, or return (DD-MMM-YYYY).
Courier Tracking / Invoice # Traceability back to the physical shipping container and packing manifest.
Kit Number / Bottle ID Unique serial number identifying the specific packaging unit transacted.
Lot / Batch Number Manufacturing batch identifier corresponding to the Certificate of Analysis.
Expiration / Retest Date Validates that no expired or outdated product was dispensed to participants.
Subject ID & Initials Unique screening/randomization code of the participant receiving the drug.
Quantity Dispensed Exact number of tablets, capsules, vials, or devices given to the subject.
Quantity Returned Exact count of unused dosage units brought back by the subject at the next visit.
Quantity Damaged / Lost / Wasted Spilled, dropped, broken, or unreturned units with explanatory notes.
Balance on Hand Running mathematical tally of usable units remaining in site storage.
Dispenser Signature / Initials Legible signature/initials of the authorized, delegated staff member dispensing IP.
ALCOAC Principle in IP Logging: IPAL entries must be made in real-time at the exact moment of receipt, dispensing, or return. Back-dating, delayed batch-logging at the end of the week, or erasing pencil notes violates ALCOAC (Attributable, Legible, Contemporaneous, Original, Accurate, Complete) standards.
3. Dispensing Procedures & Dose Modifications
Dispensing investigational medication is a highly controlled clinical workflow requiring multiple cross-checks prior to handing the product to the participant. ┌───────────────────────────────────────────────────────────────────────────┐
- │ THE 6-POINT DISPENSING CHECKLIST │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. VERIFY INVESTIGATOR PRESCRIPTION: Confirm signed prescription/order │
- │ from an authorized Investigator/Sub-Investigator listed on Form 1572. │
- │ 2. VERIFY ELIGIBILITY & VISIT WINDOW: Confirm subject has completed all │
- │ required safety labs (e.g., liver enzymes, pregnancy test) and is │
- │ within the protocol-defined visit scheduling window. │
- │ 3. IRT / RTSM ASSIGNMENT: Query interactive web system to receive the │
- │ exact kit number assigned dynamically to that specific Subject ID. │
- │ 4. TWO-PERSON PHYSICAL VERIFICATION: Cross-check kit ID on the physical │
- │ box against the IRT allocation screen and the prescription. │
- │ 5. AFFIX PATIENT-SPECIFIC LABEL: Add Subject ID, visit number, date, and │
- │ detailed dosing instructions per local pharmacy regulations. │
- │ 6. PATIENT COUNSELING: Verbally review dosing instructions, missed dose │
- │ rules, dietary restrictions, storage conditions, and the requirement │
- │ to return all unused medication and empty bottles at the next visit. │
- └───────────────────────────────────────────────────────────────────────────┘
- Dose Titrations, Reductions, and Interruptions
When a protocol specifies dose modifications (e.g., reducing from 100 mg daily to 50 mg daily due to Grade 2 thrombocytopenia):
The PI must write a formal dose modification order in the medical source records.
The IRT system must be updated with the dose level adjustment.
The exact kit containing the reduced strength must be dispensed, and the dose modification documented on the IPAL with a corresponding medical explanatory note.
4. Subject Compliance Verification & Pill Count Calculations
At every protocol return visit, research staff must perform physical medication reconciliation and calculate the subject's therapeutic compliance rate.
The Standard Medication Adherence Formula Medication Compliance (%) = ( Quantity Dispensed − Quantity Returned Quantity Expected to be Consumed ) × 100 % \text{Medication Compliance (\%)} = \left( \frac{\text{Quantity Dispensed} - \text{Quantity Returned}}{\text{Quantity Expected to be Consumed}} \right) \times 100\% Medication Compliance (%) = ( Quantity Expected to be Consumed Quantity Dispensed − Quantity Returned ) × 100% Where: Quantity Expected = Prescribed Doses per Day × Number of Days Between Visits \text{Where: Quantity Expected} = \text{Prescribed Doses per Day} \times \text{Number of Days Between Visits} Where: Quantity Expected = Prescribed Doses per Day × Number of Days Between Visits
Practical Mathematical Compliance Calculation ┌───────────────────────────────────────────────────────────────────────────┐
- │ SAMPLE ADHERENCE CALCULATION CASE │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ • Protocol Dosing: 2 capsules orally once daily │
- │ • Visit Interval: 28 days between Visit 2 (Dispense) and Visit 3 (Return)│
- │ • Quantity Dispensed at Visit 2: 60 capsules (30-day supply) │
- │ • Quantity Returned at Visit 3: 8 capsules │
- │ │
- │ CALCULATION: │
- │ 1. Actual Consumed = 60 dispensed - 8 returned = 52 capsules consumed │
- │ 2. Expected Consumed = 2 capsules/day * 28 days = 56 capsules expected │
- │ 3. Compliance Rate = (52 / 56) * 100% = 92.86% │
- │ │
- │ EVALUATION: Compliance is 92.9% (Falls within acceptable 80% - 120% range)│
- └───────────────────────────────────────────────────────────────────────────┘
- Managing Compliance Outliers (<80% or >120%)
Under-Compliance (<80%): Subject took fewer doses than prescribed (e.g., missed doses due to nausea or forgetfulness). Staff must retrain the subject, explore adherence barriers, document reasons in source records, and evaluate whether protocol non-compliance criteria are met.
Over-Compliance (>120%): Subject took more medication than prescribed (e.g., doubling doses after forgetting). The PI must immediately evaluate the subject for toxicity, report potential overdose if required by the protocol, and re-educate the participant.
Lost or Discarded Units: If a participant loses a blister strip or throws away empty bottles, staff must document the subject's verbal accounting in source records and mark the units as 'Lost by Subject' on the IPAL (never assume or fabricate returned counts).
5. IP Return, Final Reconciliation & Destruction Procedures
At the conclusion of a clinical trial or following protocol-defined intervals, all investigational products must undergo 100% final mathematical reconciliation . ┌───────────────────────────────────────────────────────────────────────────┐
- │ 100% FINAL IP RECONCILIATION EQUATION │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ TOTAL UNITS RECEIVED │
- │ EQUALS (=) │
- │ TOTAL UNITS DISPENSED (Consumed + Returned) │
- │ PLUS (+) │
- │ TOTAL UNUSED UNITS REMAINING IN INVENTORY │
- │ PLUS (+) │
- │ TOTAL UNITS DAMAGED, LOST, OR WASTED (Documented) │
- └───────────────────────────────────────────────────────────────────────────┘
- Disposition Pathway: Return to Depot vs. On-Site Destruction
Once the monitor (CRA) completes physical source data verification and counts all unused and returned IP, the final disposition occurs via one of two authorized pathways: ┌──────────────────────────────────┐
- │ FINAL IP RECONCILIATION BY CRA │
- └─────────────────┬────────────────┘
- │
- ┌─────────────────────────┴─────────────────────────┐
- ▼ ▼
- ┌───────────────────────────┐ ┌───────────────────────────┐
- │ PATHWAY A: RETURN DEPOT │ │ PATHWAY B: DESTRUCTION │
- │ • Pack returned & unused │ │ • Prior written sponsor OK│
- │ • Complete return manifest│ │ • Institutional biohazard │
- │ • Courier chain-of-custody│ │ • 2 witness signatures │
- │ • Depot receives & signs │ │ • Cert of Destruction │
- └───────────────────────────┘ └───────────────────────────┘
Mandatory Requirements for On-Site Destruction:
Prior Written Sponsor Authorization: Sites must never destroy investigational drug on site based on verbal discussions. Formal written approval (e.g., an executed Sponsor IP Destruction Authorization Letter ) is legally mandatory.
Compliance with Local Environmental & Hazardous Waste Laws: Cytotoxic agents, biologics, or chemical toxins must be incinerated or processed via licensed biohazard waste vendors in compliance with EPA/local environmental regulations.
Controlled Substances (DEA Rules): Destruction of Schedule II-V investigational narcotics must comply with 21 CFR Part 1317 and DEA regulations, requiring DEA Form 41 (Registrant Record of Controlled Substances Destroyed) and submission to the DEA Field Division.
Certificate of Destruction: A comprehensive legal document executed immediately upon destruction, detailing:
- Protocol number and site number
- Product name, dosage form, and strength
- Lot/batch numbers and kit serial numbers destroyed
- Exact quantity destroyed (in units/tablets/vials)
- Method of destruction (e.g., high-temperature incineration, chemical denaturation)
- Date, time, and physical location of destruction
Printed names and signatures of at least two qualified witnesses (e.g., the Research Pharmacist and the Principal Investigator or Quality Manager).
6. Realistic Clinical Scenario & ACRP-CP Case Analysis
Clinical Scenario: A Clinical Research Associate (CRA) is conducting a close-out monitoring visit at an investigational site for a completed Phase III diabetes study. During final IP reconciliation, the CRA identifies the following discrepancies between the pharmacy inventory and the Master IPAL:
The Master IPAL indicates that 100 kits of GLUC-10 were received. 80 kits were dispensed to subjects, and 20 unused kits remain in the pharmacy vault. However, a physical count of the vault reveals only 18 unused kits (2 kits missing).
For Subject #105 at Visit 4, the coordinator documented that the subject returned 0 tablets out of 60 dispensed. The coordinator wrote in the source notes: "Subject states he threw the empty bottle into the municipal recycling bin after taking the last dose."
The site pharmacist destroyed 10 expired return kits in the hospital incinerator two weeks prior to the close-out visit without notifying the sponsor, stating that "hospital SOP requires destroying expired drugs immediately."
ACRP-CP Compliance Evaluation & Audit Resolution:
Finding 1 Resolution (Missing Kits): The discrepancy of 2 missing kits represents an unresolved inventory imbalance. The site must conduct an immediate physical search and audit trail review of all dispensing logs and IRT transactions. If the kits cannot be located, the PI must file a formal Missing IP Incident Report , document the loss on the Master IPAL, execute a root-cause investigation, and submit the report to the sponsor and IRB.
Finding 2 Resolution (Subject Discarded Bottle): The coordinator correctly recorded the subject's verbal explanation in the source record. On the IPAL, the coordinator must record: "Quantity Returned: 0 (60 tablets consumed per subject interview; empty container discarded by subject)." Staff must never record unreturned containers as returned or alter numbers to make logs balance.
Finding 3 Resolution (Unauthorized Destruction Violation): The pharmacist's unauthorized destruction of expired study drug is a major GCP non-compliance violation . Site SOPs cannot override GCP requirements for sponsor authorization. The site must issue an urgent deviation notification, obtain an after-the-fact statement from the incineration facility, execute a formal corrective and preventive action (CAPA) plan, and retrain pharmacy staff on sponsor destruction workflows.